BiomX Inc. (PHGE)
- Previous Close
0.5467 - Open
0.5560 - Bid 0.2255 x 1000
- Ask --
- Day's Range
0.5303 - 0.5800 - 52 Week Range
0.4770 - 4.9000 - Volume
61,932 - Avg. Volume
124,591 - Market Cap (intraday)
14.073M - Beta (5Y Monthly) 1.52
- PE Ratio (TTM)
-- - EPS (TTM)
-1.4700 - Earnings Date Aug 13, 2025 - Aug 18, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
18.50
BiomX Inc., a clinical-stage biopharmaceutical company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria associated with chronic diseases. The company is developing BX211, a phage therapy, which is in phase 2 clinical study for the treatment of diabetic foot osteomyelitis. It also developing BX004, a phage therapy for cystic fibrosis and non-cystic fibrosis bronchiectasis patients with chronic pulmonary infections caused by Pseudomonas aeruginosa that is in Phase 1b/2a clinical trials. The company was founded in 2015 and is headquartered in Ness Ziona, Israel.
www.biomx.comRecent News: PHGE
View More
Performance Overview: PHGE
Trailing total returns as of 5/15/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: PHGE
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: PHGE
View MoreValuation Measures
Market Cap
14.07M
Enterprise Value
25.45M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
2.56
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-65.10%
Return on Equity (ttm)
-130.21%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-17.73M
Diluted EPS (ttm)
-1.4700
Balance Sheet and Cash Flow
Total Cash (mrq)
16.86M
Total Debt/Equity (mrq)
39.69%
Levered Free Cash Flow (ttm)
-17.67M